Relationship between prostaglandin E2 and vascular endothelial growth factor (VEGF) in angiogenesis in human vascular endothelial cells

Vascular Pharmacology

Volumn 44, Issue 6, 2006, Pages 411-416

  Tamura, Kazuhiro ^a   Sakurai, Toshihiro ^a   Kogo, Hiroshi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Angiogenesis; Cyclooxygenase 2; Prostaglandin E2; Vascular endothelial growth factor

Indexed keywords

5,8,11,14 ICOSATETRAYNOIC ACID; MESSENGER RNA; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; RECOMBINANT VASCULOTROPIN; SU 5614; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN INHIBITOR; COLLAGEN; CYCLOOXYGENASE 2; ISOMERASE; LAMININ; LIPOXYGENASE INHIBITOR; MATRIGEL; MEMBRANE PROTEIN; PROSTAGLANDIN E SYNTHASE; PROTEIN KINASE INHIBITOR; PROTEOGLYCAN; PTGS2 PROTEIN, HUMAN; RECOMBINANT PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; DOSE RESPONSE; DRUG COMBINATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

5,8,11,14-EICOSATETRAYNOIC ACID; CELLS, CULTURED; COLLAGEN; CYCLOOXYGENASE 2; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; LAMININ; LIPOXYGENASE INHIBITORS; MEMBRANE PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN KINASE INHIBITORS; PROTEOGLYCANS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT PROTEINS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33646760266     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.02.009     Document Type: Article

References (41)

1. Akarasereenont P., Techatraisak K., Thaworn A., and Chotewuttakorn S. The induction of cyclooxygenase-2 by 17beta-estradiol in endothelial cells is mediated through protein kinase C. Inflamm. Res. 49 (2000) 460-465
2. Amano H., Haysahi I., Yoshida S., Yoshimura H., and Majima M. Cyclooxygenase-2 and adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Hum. Cell 15 (2002) 13-24
3. Camacho M., Lopez-Belmonte J., and Vila L. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Circ. Res. 83 (1998) 353-365
4. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9 (2003) 653-660
5. 2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 591-596
6. 2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest. Ophthalmol. Vis. Sci. 39 (1998) 581-591
7. Cianchi F., Cortesini C., Bechi P., Fantappie O., Messerini L., Vannacci A., Sardi I., Baroni G., Boddi V., Mazzanti R., and Masini E. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 121 (2001) 1339-1347
8. 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 59 (1999) 4574-4577
9. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18 (1997) 4-25
10. Folkman J., and D'Amore P.A. Blood vessel formation: what is its molecular basis?. Cell 87 (1996) 1153-1155
11. 2 and angiogenesis. Proc. Soc. Exp. Biol. Med. 172 (1983) 214-218
12. Gallo O., Franchi A., Magnelli L., Sardi I., Vannacci A., Boddi V., Chiarugi V., and Masini E. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3 (2001) 53-61
13. Gately S., and Li W.W. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin. Oncol. 31 (2004) 2-11
14. Hahn G.L., and Polgar P.R. Prostaglandin production in phenotypically distinct cultured bovine pulmonary artery endothelium. Atherosclerosis 51 (1984) 143-150
15. He H., Venema V.J., Gu X., Venema R.C., Marrero M.B., and Caldwell R.B. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J. Biol. Chem. 274 (1999) 25130-25135
16. Hernandez G.L., Volpert O.V., Iniguez M.A., Lorenzo E., Martinez-Martinez S., Grau R., Fresno M., and Redondo J.M. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J. Exp. Med. 193 (2001) 607-620
17. Hla T., Ristimaki A., Appleby S., and Barriocanal J.G. Cyclooxygenase gene expression in inflammation and angiogenesis. Ann. N. Y. Acad. Sci. 696 (1993) 197-204
18. 2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br. J. Pharmacol. 136 (2002) 287-295
19. Jantke J., Ladehoff M., Kurzel F., Zapf S., Kim E., and Giese A. Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis. Acta. Neurochir. (Wien) 146 (2004) 483-494
20. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., and Tarnawski A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5 (1999) 1418-1423
21. Kage K., Fujita N., Oh-hara T., Ogata E., Fujita T., and Tsuruo T. Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone. Biochem. Biophys. Res. Commun. 254 (1999) 259-263
22. Kuwano T., Nakao S., Yamamoto H., Tsuneyoshi M., Yamamoto T., Kuwano M., and Ono M. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J. 18 (2004) 300-310
23. Kuwashima L., Graeber J., and Glaser B.M. Stimulation of endothelial cell prostacyclin release by retina-derived factors. Invest. Ophthalmol. Vis. Sci. 29 (1988) 1213-1220
24. Leahy K.M., Koki A.T., and Masferrer J.L. Role of cyclooxygenases in angiogenesis. Curr. Med. Chem. 7 (2000) 1163-1170
25. 2 and arachidonic acid to prostacyclin by cultured human endothelial cells. J. Biol. Chem. 253 (1978) 7138-7141
26. Murakami M., Nakatani Y., Tanioka T., and Kudo I. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat. 68-69 (2002) 383-399
27. 2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J. Biol. Chem. 278 (2003) 37937-37947
28. Murohara T., Horowitz J.R., Silver M., Tsurumi Y., Chen D., Sullivan A., and Isner J.M. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97 (1998) 99-107
29. Murphy J.F., and Fitzgerald D.J. Vascular endothelial growth factor induces cyclooxygenase-dependent proliferation of endothelial cells via the VEGF-2 receptor. FASEB J. 15 (2001) 1667-1669
30. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13 (1999) 9-22
31. Nie D., Tang K., Diglio C., and Honn K.V. Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. Blood 95 (2000) 2304-2311
32. Park J.E., Keller G.A., and Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4 (1993) 1317-1326
33. 2 stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem. Biophys. Res. Commun. 286 (2001) 923-928
34. Sakurai T., Tamura K., Okamoto S., Hara T., and Kogo H. Possible role of cyclooxygenase II in the acquisition of ovarian luteal function in rodents. Biol. Reprod. 69 (2003) 835-842
35. Sakurai T., Tamura K., and Kogo H. Vascular endothelial growth factor increases messenger RNAs encoding cyclooxygenase-II and membrane-associated prostaglandin E synthase in rat luteal cells. J. Endocrinol. 183 (2004) 527-533
36. Sakurai T., Tamura K., and Kogo H. Stimulatory effects of eicosanoids on ovarian angiogenesis in early luteal phase in cyclooxygenase-2 inhibitor-treated. Eur. J. Pharmacol. 516 (2005) 158-164
37. 2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood 102 (2003) 1966-1977
38. Shweiki D., Itin A., Soffer D., and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992) 843-845
39. Tamura M., Sebastian S., Gurates B., Yang S., Fang Z., and Bulun S.E. Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells. J. Clin. Endocrinol. Metab. 87 (2002) 3504-3507
40. 2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett. 420 (1997) 28-32
41. 1 and copper in angiogenesis. J. Natl. Cancer Inst. 69 (1982) 475-482